{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:10:41Z","timestamp":1794852641970,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00399681"],"award-info":[{"award-number":["RS-2024-00399681"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00339289"],"award-info":[{"award-number":["RS-2024-00339289"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["RS-2023-00258714"],"award-info":[{"award-number":["RS-2023-00258714"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that begins with motor neuron death in the spinal cord and cerebral cortex, ultimately resulting in death from respiratory distress (breathing failure). About 90% of ALS cases are sporadic, and 10% of ALS cases are of the inherited type with a genetic cause. About 150 different gene mutations have been reported so far.\n                      <jats:italic>SOD1<\/jats:italic>\n                      is a well-identified gene associated with ALS. Indeed, SOD1 aggregation has been reported in ALS patients, but the mechanism of SOD1 aggregation remains unclear. Our previous work showed that inhibiting SOD1 aggregation with a hit compound (PRG-A-01) could reduce the SOD1-induced cytotoxicity and extend the lifespan of ALS mouse model (SOD1\n                      <jats:sup>G93A\u2212Tg<\/jats:sup>\n                      ). However, the low bioavailability and rapid degradation of the compound in vivo necessitates the development of a more effective candidate. We generated different derivatives and finally obtained the most potential drug candidate, PRG-A-04.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Neuronal cell lines were transfected with the mutant SOD1 expression vector and incubated with PRG-A-04. SOD1 aggregation was examined by SOD1 oligomerization assay, immunofluorescence and dot blot assay. The interaction between GST-conjugated SOD1 recombinant proteins and PRG-A-04 was identified using LC\u2013MS\/MS and GST pull-down assay. To check the in vivo therapeutic effect of PRG-A-04, SOD1\n                      <jats:sup>G93A\u2212Tg<\/jats:sup>\n                      mice were injected with PRG-A-04; then behavioral test, histological analysis and microarray were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PRG-A-04 demonstrated favorable pharmacokinetics including high bioavailability and significant blood\u2013brain barrier penetration. Indeed, oral administration of PRG-A-04 in ALS mouse model inhibited the aggregation of SOD1 in the spinal cord, protected against neuronal loss, and extended the lifespan of ALS mice by up to 3\u00a0weeks. In vitro, PRG-A-04 selectively bound to the mutant form of SOD1, but not the wild type, and efficiently inhibited the aggregation caused by SOD1-G147P (a SOD1 trimer stabilizer).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings underscore the potential of targeting trimeric SOD1 in ALS treatment, positioning PRG-A-04 as a strong drug candidate for both familial and sporadic ALS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40035-025-00483-8","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T22:57:46Z","timestamp":1747004266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibition of SOD1 trimerization is a novel drug target for ALS disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Tae-Gyun","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young jun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mua","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-mi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeongseon","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Ho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyoung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunbyeol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Minju-Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyewon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jeong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghoon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6037-7219","authenticated-orcid":false,"given":"Bum-Joon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"4","key":"483_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ncl.2015.07.006","volume":"33","author":"JM Statland","year":"2015","unstructured":"Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM. Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):735\u201348.","journal-title":"Neurol Clin"},{"issue":"5","key":"483_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","volume":"32","author":"E Longinetti","year":"2019","unstructured":"Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771\u20136.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"483_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000516752","volume":"55","author":"CA Brown","year":"2021","unstructured":"Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021;55(5):342\u201353.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"483_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162\u201372.","journal-title":"N Engl J Med"},{"issue":"3","key":"483_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22(3):185\u2013212.","journal-title":"Nat Rev Drug Discov"},{"key":"483_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00225-y","volume":"10","author":"X Xu","year":"2021","unstructured":"Xu X, Shen D, Gao Y, Zhou Q, Ni Y, Meng H, et al. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Transl Neurodegen. 2021;10:1\u201318.","journal-title":"Transl Neurodegen"},{"key":"483_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","volume":"9","author":"D Petrov","year":"2017","unstructured":"Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20\u00a0years of failure. Are we any closer to registering a new treatment. Front Aging Neurosci. 2017;9:68.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"483_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","volume":"82","author":"A Chi\u00f2","year":"2011","unstructured":"Chi\u00f2 A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"483_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1598-x","volume":"16","author":"GB Chiarotto","year":"2019","unstructured":"Chiarotto GB, Cartarozzi LP, Perez M, Biscola NP, Spejo AB, Gubert F, et al. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1 G93A) of ALS. J Neuroinflammation. 2019;16:1\u201314.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"483_CR10","doi-asserted-by":"publisher","first-page":"e65976","DOI":"10.1371\/journal.pone.0065976","volume":"8","author":"J Li","year":"2013","unstructured":"Li J, Sung M, Rutkove SB. Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice. PLoS One. 2013;8(6):e65976.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"483_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0022-510X(00)00423-8","volume":"180","author":"P Kennel","year":"2000","unstructured":"Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann J, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci. 2000;180(1\u20132):55\u201361.","journal-title":"J Neurol Sci"},{"issue":"7","key":"483_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505\u201312.","journal-title":"Lancet Neurol"},{"issue":"8","key":"483_CR13","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558\u201367.","journal-title":"J Clin Invest"},{"issue":"12","key":"483_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099\u2013110.","journal-title":"N Engl J Med"},{"issue":"52","key":"483_CR15","doi-asserted-by":"publisher","first-page":"45083","DOI":"10.1074\/jbc.M111.293282","volume":"286","author":"L Suaud","year":"2011","unstructured":"Suaud L, Miller K, Panichelli AE, Randell RL, Marando CM, Rubenstein RC. 4-Phenylbutyrate stimulates Hsp70 expression through the Elp2 component of elongator and STAT-3 in cystic fibrosis epithelial cells. J Biol Chem. 2011;286(52):45083\u201392.","journal-title":"J Biol Chem"},{"issue":"10","key":"483_CR16","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1021\/bi026979d","volume":"42","author":"CM Rodrigues","year":"2003","unstructured":"Rodrigues CM, Sol\u00e1 S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry. 2003;42(10):3070\u201380.","journal-title":"Biochemistry"},{"issue":"3","key":"483_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.28182","volume":"70","author":"T Meyer","year":"2024","unstructured":"Meyer T, Schumann P, Weydt P, Petri S, Weishaupt JH, Weyen U, et al. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS\u2014A multicenter observational study over 18 months. Muscle Nerve. 2024;70(3):333\u201345.","journal-title":"Muscle Nerve"},{"issue":"2","key":"483_CR18","first-page":"216","volume":"29","author":"D Nikitin","year":"2023","unstructured":"Nikitin D, Makam AN, Suh K, McKenna A, Carlson JJ, Richardson M, et al. The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: a summary from the institute for clinical and economic review\u2019s midwest comparative effectiveness public advisory council. J Manag Care Spec Pharm. 2023;29(2):216\u201321.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"483_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23(2):1\u201313.","journal-title":"Nat Med"},{"issue":"1","key":"483_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.","journal-title":"Nat Rev Dis Primers"},{"key":"483_CR21","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"483_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2(7):492\u2013501.","journal-title":"Nat Rev Neurosci"},{"issue":"7628","key":"483_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature20413","volume":"539","author":"JP Taylor","year":"2016","unstructured":"Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197\u2013206.","journal-title":"Nature"},{"key":"483_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41589-024-01672-8","volume":"20","author":"K Neupane","year":"2024","unstructured":"Neupane K, Narayan A, Sen Mojumdar S, Adhikari G, Garen CR, Woodside MT. Direct observation of prion-like propagation of protein misfolding templated by pathogenic mutants. Nat Chem Biol. 2024;20:1\u20137.","journal-title":"Nat Chem Biol"},{"key":"483_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-017-1688-8","volume":"134","author":"S Da Cruz","year":"2017","unstructured":"Da Cruz S, Bui A, Saberi S, Lee SK, Stauffer J, McAlonis-Downes M, et al. Misfolded SOD1 is not a primary component of sporadic ALS. Acta Neuropathol. 2017;134:97\u2013111.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"483_CR26","doi-asserted-by":"publisher","first-page":"e200196","DOI":"10.1212\/NXG.0000000000200196","volume":"10","author":"A Nishiyama","year":"2024","unstructured":"Nishiyama A, Niihori T, Suzuki N, Izumi R, Akiyama T, Kato M, et al. Updated genetic analysis of Japanese familial ALS patients carrying SOD1 variants revealed phenotypic Differences for common variants. Neurol Genet. 2024;10(6):e200196.","journal-title":"Neurol Genet"},{"key":"483_CR27","doi-asserted-by":"publisher","first-page":"1408159","DOI":"10.3389\/fnmol.2024.1408159","volume":"17","author":"J Min","year":"2024","unstructured":"Min J, Harris RA, Sarlus H. Copper toxicity and deficiency: the vicious cycle at the core of protein aggregation in ALS. Front Mol Neurosci. 2024;17:1408159.","journal-title":"Front Mol Neurosci"},{"key":"483_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fncel.2013.00253","volume":"7","author":"MS Rotunno","year":"2013","unstructured":"Rotunno MS, Bosco DA. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front Cell Neurosci. 2013;7:253.","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"483_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/nn.2660","volume":"13","author":"DA Bosco","year":"2010","unstructured":"Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(11):1396\u2013403.","journal-title":"Nat Neurosci"},{"issue":"8","key":"483_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/jnnp-2018-319386","volume":"90","author":"K Forsberg","year":"2019","unstructured":"Forsberg K, Graffmo K, Pakkenberg B, Weber M, Nielsen M, Marklund S, et al. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS\/FTD-associated genes. J Neurol Neurosurg Psychiatry. 2019;90(8):861\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"483_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.21147","volume":"61","author":"IR Mackenzie","year":"2007","unstructured":"Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427\u201334.","journal-title":"Ann Neurol"},{"issue":"1","key":"483_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s42003-021-02862-z","volume":"4","author":"T Woo","year":"2021","unstructured":"Woo T, Yoon M, Kang S, Park S, Cho J, Hwang YJ, et al. Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model. Commun Biol. 2021;4(1):1397.","journal-title":"Commun Biol"},{"issue":"4","key":"483_CR33","doi-asserted-by":"publisher","first-page":"e35050","DOI":"10.1371\/journal.pone.0035050","volume":"7","author":"E Pokrishevsky","year":"2012","unstructured":"Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PloS One. 2012;7(4):e35050.","journal-title":"PloS One"},{"issue":"4","key":"483_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693\u2013714.","journal-title":"Cell"},{"issue":"7","key":"483_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41576-018-0011-4","volume":"19","author":"C Scheckel","year":"2018","unstructured":"Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nat Rev Genetics. 2018;19(7):405\u201318.","journal-title":"Nat Rev Genetics"},{"issue":"20","key":"483_CR36","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","volume":"344","author":"SB Prusiner","year":"2001","unstructured":"Prusiner SB. Neurodegenerative diseases and prions. N Engl J Med. 2001;344(20):1516\u201326.","journal-title":"N Engl J Med"},{"key":"483_CR37","doi-asserted-by":"publisher","first-page":"581907","DOI":"10.3389\/fncel.2020.581907","volume":"14","author":"L McAlary","year":"2020","unstructured":"McAlary L, Chew YL, Lum JS, Geraghty NJ, Yerbury JJ, Cashman NR. Amyotrophic lateral sclerosis: proteins, proteostasis, prions, and promises. Front Cell Neurosci. 2020;14:581907.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"483_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jnnp-2020-322983","volume":"92","author":"EMJ Boer","year":"2021","unstructured":"Boer EMJ, De Orie VK, Williams T, Baker MR, De Oliveira HM, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2021;92(1):86\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"18","key":"483_CR39","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1073\/pnas.1800187115","volume":"115","author":"C Zhu","year":"2018","unstructured":"Zhu C, Beck MV, Griffith JD, Deshmukh M, Dokholyan NV. Large SOD1 aggregates, unlike trimeric SOD1; do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2018;115(18):4661\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"483_CR40","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1073\/pnas.1516725113","volume":"113","author":"EA Proctor","year":"2016","unstructured":"Proctor EA, Fee L, Tao Y, Redler RL, Fay JM, Zhang Y, et al. Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2016;113(3):614\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"483_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.sbi.2020.12.002","volume":"66","author":"ES Choi","year":"2021","unstructured":"Choi ES, Dokholyan NV. SOD1 oligomers in amyotrophic lateral sclerosis. Curr Opin Struct Biol. 2021;66:225\u201330.","journal-title":"Curr Opin Struct Biol"},{"issue":"11","key":"483_CR42","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.bpj.2022.04.037","volume":"121","author":"B Hnath","year":"2022","unstructured":"Hnath B, Dokholyan NV. Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS. Biophys J. 2022;121(11):2084\u201395.","journal-title":"Biophys J"},{"issue":"3","key":"483_CR43","doi-asserted-by":"publisher","first-page":"e0298196","DOI":"10.1371\/journal.pone.0298196","volume":"19","author":"S Unni","year":"2024","unstructured":"Unni S, Kommu P, Aouti S, Nalli Y, Bharath MS, Ali A, et al. Structural insights into the modulation Of SOD1 aggregation By a fungal metabolite Phialomustin-B: therapeutic potential in ALS. PloS One. 2024;19(3):e0298196.","journal-title":"PloS One"},{"issue":"39","key":"483_CR44","doi-asserted-by":"publisher","first-page":"26833","DOI":"10.1039\/D3CP03978A","volume":"25","author":"A Rahman","year":"2023","unstructured":"Rahman A, Saikia B, Baruah A. In silico analysis of SOD1 aggregation inhibition modes of tertiary amine pyrazolone and pyrano coumarin ferulate as ALS drug candidates. Phys Chem Chem Phys. 2023;25(39):26833\u201346.","journal-title":"Phys Chem Chem Phys"},{"issue":"470","key":"483_CR45","doi-asserted-by":"publisher","first-page":"eaah3924","DOI":"10.1126\/scitranslmed.aah3924","volume":"10","author":"M Maier","year":"2018","unstructured":"Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci Transl Med. 2018;10(470):eaah3924.","journal-title":"Sci Transl Med."},{"key":"483_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12964-015-0102-1","volume":"13","author":"G Preta","year":"2015","unstructured":"Preta G, Cronin JG, Sheldon IM. Dynasore-not just a dynamin inhibitor. Cell Commun Signal. 2015;13:24.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"483_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev.ne.13.030190.001131","volume":"13","author":"DW Choi","year":"1990","unstructured":"Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990;13(1):171\u201382.","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"483_CR48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1474-9726.2007.00275.x","volume":"6","author":"MP Mattson","year":"2007","unstructured":"Mattson MP. Calcium and neurodegeneration. Aging Cell. 2007;6(3):337\u201350.","journal-title":"Aging Cell"},{"issue":"5","key":"483_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrn2373","volume":"9","author":"LA Cingolani","year":"2008","unstructured":"Cingolani LA, Goda Y. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat Rev Neurosci. 2008;9(5):344\u201356.","journal-title":"Nat Rev Neurosci"},{"issue":"10","key":"483_CR50","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrn3801","volume":"15","author":"CJ Stam","year":"2014","unstructured":"Stam CJ. Modern network science of neurological disorders. Nat Rev Neurosci. 2014;15(10):683\u201395.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"483_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJ. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9\u201321.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"483_CR52","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00018-023-04956-9","volume":"80","author":"T Guan","year":"2023","unstructured":"Guan T, Zhou T, Zhang X, Guo Y, Yang C, Lin J, et al. Selective removal of misfolded SOD1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. Cell Mol Life Sci. 2023;80(10):304.","journal-title":"Cell Mol Life Sci"},{"key":"483_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.intimp.2018.10.032","volume":"65","author":"Q Dong","year":"2018","unstructured":"Dong Q, Zhu J, Liu S, Yu X, Liu R. An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS. Int Immunopharmacol. 2018;65:413\u201321.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"483_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1083\/jcb.201408092","volume":"209","author":"A Aulas","year":"2015","unstructured":"Aulas A, Caron G, Gkogkas CG, Mohamed N, Destroismaisons L, Sonenberg N, et al. G3BP1 promotes stress-induced RNA granule interactions to preserve polyadenylated mRNA. J Cell Biol. 2015;209(1):73.","journal-title":"J Cell Biol"},{"issue":"2","key":"483_CR55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/hmg\/ddac206","volume":"32","author":"A Dubinski","year":"2023","unstructured":"Dubinski A, Gagn\u00e9 M, Peyrard S, Gordon D, Talbot K, Vande VC. Stress granule assembly in vivo is deficient in the CNS of mutant TDP-43 ALS mice. Hum Mol Genet. 2023;32(2):319\u201332.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"483_CR56","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/hmg\/ddr021","volume":"20","author":"KK McDonald","year":"2011","unstructured":"McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011;20(7):1400\u201310.","journal-title":"Hum Mol Genet"},{"key":"483_CR57","doi-asserted-by":"publisher","first-page":"102085","DOI":"10.1016\/j.arr.2023.102085","volume":"92","author":"A Babazadeh","year":"2023","unstructured":"Babazadeh A, Rayner SL, Lee A, Chung RS. TDP-43 as a therapeutic target in neurodegenerative diseases; focusing on motor neuron disease and frontotemporal dementia. Ageing Res Rev. 2023;92:102085.","journal-title":"Ageing Res Rev"},{"issue":"11","key":"483_CR58","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1093\/brain\/awab217","volume":"144","author":"H Sidib\u00e9","year":"2021","unstructured":"Sidib\u00e9 H, Khalfallah Y, Xiao S, G\u00f3mez NB, Fakim H, Tank EM, et al. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis\/frontotemporal dementia. Brain. 2021;144(11):3461\u201376.","journal-title":"Brain"},{"issue":"2","key":"483_CR59","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","volume":"22","author":"Z Melamed","year":"2019","unstructured":"Melamed Z, L\u00f3pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180\u201390.","journal-title":"Nat Neurosci"},{"issue":"2","key":"483_CR60","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","volume":"22","author":"JR Klim","year":"2019","unstructured":"Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2; a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167\u201379.","journal-title":"Nat Neurosci"},{"issue":"11","key":"483_CR61","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1172\/JCI139741","volume":"130","author":"M Prudencio","year":"2020","unstructured":"Prudencio M, Humphrey J, Pickles S, Brown A, Hill SE, Kachergus JM, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11):6080.","journal-title":"J Clin Invest"},{"issue":"6637","key":"483_CR62","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1126\/science.abq5622","volume":"379","author":"MW Baughn","year":"2023","unstructured":"Baughn MW, Melamed Z, L\u00f3pez-Erauskin J, Beccari MS, Ling K, Zuberi A, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140\u20139.","journal-title":"Science"},{"issue":"1","key":"483_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41392-023-01533-1","volume":"8","author":"S Menge","year":"2023","unstructured":"Menge S, Decker L, Freischmidt A. Restoring expression of Stathmin-2: a novel strategy to treat TDP-43 proteinopathies. Signal Transduct Target Ther. 2023;8(1):266.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"483_CR64","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1172\/JCI90607","volume":"127","author":"D Lall","year":"2017","unstructured":"Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest. 2017;127(9):3250\u20138.","journal-title":"J Clin Invest"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00483-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-025-00483-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00483-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:04:34Z","timestamp":1747047874000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-025-00483-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1186\/s40035-025-00483-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5394854\/v1","asserted-by":"object"}]},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}